| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Inspire Medical Systems, Inc.$51.76
+0.24 (+0.47%)
D 29Pipeline Score MedTech · Commercial
Market Cap
1.26 B
EPS
4.53
P/E Ratio
9.8 $
Value Trade
45.84 M
SEC Financials
Q1 2026Dilution Risk
Revenue
204.58 M
R&D Expenses
25.83 M
Operating CF
12.85 M
Total Assets
911.38 M
Total Liabilities
119.04 M
Equity
792.34 M
D/E Ratio
12,345
1.25 %
Week
-16.97 %
1 Month
-25.9 %
3 Month
-47.5 %
6 Month
-76.51 %
5 Year
79.01 %
All Time
Cash Data
Cash Position
283.83 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 4, 2026
Overview
Volume
1.29 M
52 Week Range
39.61 - 147.66
% held by Insiders
5.7 %
% held by Institutions
117.85 %
Enterprise Value
1.01 B
Total Shares
28.79 M
Short %
13.21 %
Float Shares
28.13 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D29
Pipeline Score $0M
Pipeline ValueValuation Signal
1
Drugs Scored—
rNPV / MCap Top 33%
Micro Cap (rank 611 of 911)
Percentile RankInspire Medical Systems, Inc. faces pipeline headwinds (29/100), with 1 assets in development.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inspire Upper Airway Stimulation System Unknown | Down Syndrome | Phase 3 | NCT04801771 | 52% | - | ACTIVE NOT_RECRUITING | 57 | STALLED | D (22) | Sep 30, 2027 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Inspire therapy | obstructive sleep apnea | — | 2026-06-16 | Significant reductions in hypoxic burden; Improvements in daytime sleepiness that correlate with hypoxic burden reduction, independent of AHI or arousal index changes; Meaningful hypoxic burden improvements in at least 50% of AHI non-responders Read More | Inspire Medical Systems, Inc. Announces Presence at SLEEP 2026 and Publication of PREDICTOR Study Read More | |
Inspire therapy | obstructive sleep apnea | — | 2026-06-16 | Significant reductions in hypoxic burden; Improvements in daytime sleepiness that correlate with hypoxic burden reduction, independent of AHI or arousal index changes; Meaningful hypoxic burden improvements in at least 50% of AHI non-responders Read More | Inspire Medical Systems, Inc. Announces Presence at SLEEP 2026 and Publication of PREDICTOR Study Read More | |
Inspire therapy | obstructive sleep apnea | — | 2026-06-16 | Significant reductions in hypoxic burden; Improvements in daytime sleepiness that correlate with hypoxic burden reduction, independent of AHI or arousal index changes; Meaningful hypoxic burden improvements in at least 50% of AHI non-responders Read More | Inspire Medical Systems, Inc. Announces Presence at SLEEP 2026 and Publication of PREDICTOR Study Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in INSP
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
INSP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
INSPCorrection: Inspire Medical Systems, Inc. to Report Second Quarter 2026 Financial Results on August 3, 2026
Inspire Medical Systems, Inc. has corrected the date for its second quarter 2026 financial results, which will now be released on August 3, 2026. The management team will host a conference call at 5:00 p.m. Eastern Time to discuss the results and recent developments. A webcast will be available for those interested in listening.
Read more →INSP▲ +5.3%on this newsshared move
Inspire Medical Systems, Inc. to Report Second Quarter 2026 Financial Results on July 6, 2026
Inspire Medical Systems, Inc. will announce its financial results for Q2 2026 on August 3, 2026. A conference call will follow at 5:00 p.m. ET to discuss these results and recent business developments. The call will be accessible via webcast, and a replay will be available afterward.
Read more →INSPInspire Medical Systems, Inc. Announces Presence at SLEEP 2026 and Publication of PREDICTOR Study
Inspire Medical Systems announced its participation in SLEEP 2026, showcasing advancements in its Inspire platform and presenting new clinical data on the effectiveness of Inspire therapy for obstructive sleep apnea (OSA). The company highlighted significant findings on hypoxic burden and cardiovascular outcomes, emphasizing the therapy's benefits over traditional CPAP. Additionally, the publication of the PREDICTOR study suggests potential for streamlined patient screening.
Read more →INSPInspire Medical Systems, Inc. to Participate in the Wells Fargo 2026 MedTech Innovation Spotlight
Inspire Medical Systems, Inc. will participate in the Wells Fargo 2026 MedTech Innovation Spotlight on June 26, 2026. The management team is scheduled to present at 10:00 a.m. ET, with a live webcast available. The presentation will be archived for two weeks on Inspire's investor website. Inspire specializes in minimally invasive solutions for obstructive sleep apnea.
Read more →INSPInspire Medical Systems, Inc. Announces First Quarter 2026 Financial Results and Updates 2026 Guidance
Inspire Medical Systems reported a 1.6% revenue growth for Q1 2026, totaling $204.6 million. Despite an operating loss of $1.1 million, the company improved its adjusted operating income and cash flow. However, ongoing challenges related to coding and reimbursement uncertainties are anticipated to affect performance throughout the year, with a revised revenue outlook for 2026 indicating a potential decline.
Read more →INSPInspire Medical Systems, Inc. to Present at the BofA Securities 2026 Healthcare Conference
Inspire Medical Systems, Inc. will present at the BofA Securities 2026 Healthcare Conference on May 13, 2026. The presentation will be available via a live webcast, with a replay accessible for two weeks afterward. Inspire specializes in minimally invasive solutions for obstructive sleep apnea, with its Inspire therapy being FDA approved.
Read more →INSPInspire Medical Systems, Inc. to Report First Quarter 2026 Financial Results on May 4, 2026
Inspire Medical Systems, Inc. will announce its financial results for the first quarter of 2026 on May 4, 2026, after market close. A conference call will follow at 5:00 p.m. ET, where management will discuss the results and recent developments. Interested parties can access the call via a webcast or register to ask questions.
Read more →INSPInspire Medical Systems, Inc. to Present at the KeyBanc Capital Markets Healthcare Forum
Inspire Medical Systems, Inc. will present at the KeyBanc Capital Markets Healthcare Forum on March 17, 2026. The presentation is scheduled for 1:30 p.m. Eastern Time and will be available via live webcast. A replay will be accessible for two weeks on Inspire's Investor website. Inspire specializes in minimally invasive solutions for obstructive sleep apnea.
Read more →INSP▼ -12.5%on this news
Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results
Inspire Medical Systems reported strong financial results for Q4 and full year 2025, highlighting the successful launch of the Inspire V system and FDA approval for 3.0T MRI compatibility. Despite a dynamic reimbursement landscape, the company remains optimistic about its growth trajectory. However, there are concerns regarding coding changes that could affect physician reimbursement rates.
Read more →INSPInspire Medical Systems, Inc. Announces Preliminary Unaudited Revenue Results for the Fourth Quarter and Full Year 2025 and Provides Initial 2026 Revenue Guidance Inspire Announces Appointment of Matt Osberg as Executive
Inspire Medical Systems, Inc. has announced preliminary unaudited revenue results for Q4 and the full year 2025, reporting significant growth of approximately 12% and 14% year-over-year, respectively. The company has provided initial revenue guidance for 2026, anticipating a 10-11% increase. Additionally, Matt Osberg has been appointed as the new CFO, effective January 19, 2026. While the results are promising, they remain subject to audit, and current outlook does not factor in potential reimbursement increases.
Read more →INSPInspire Medical Systems, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference
Inspire Medical Systems, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will highlight the company's innovative solutions for obstructive sleep apnea, including its FDA-approved Inspire therapy. A live webcast will be available, along with a replay for two weeks post-event.
Read more →INSP▼ -13.4%on this news
Inspire Medical Systems, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2024 and Provides Initial 2025 Revenue Guidance Inspire Reports Year-over-Year Revenue Growth of 25% for the Fourth Quarter
Inspire Medical Systems, Inc. announced preliminary, unaudited results for the fourth quarter and full year of 2024, reporting a revenue growth of approximately 25% for Q4 and 28% for the full year. The company has also provided initial revenue guidance for 2025, anticipating a growth of 17% to 19%. Inspire activated 72 new medical centers in the U.S. and initiated the soft launch of the Inspire V neurostimulator. Additionally, the company outlined a new organizational structure aimed at fueling continued growth and enhancing therapy adoption.
Read more →INSP▲ +6.2%on this news
Inspire Medical Systems, Inc. Announces Preliminary Results for Second Quarter of 2024 and Updates 2024 Revenue Outlook MINNEAPOLIS, MN
Inspire Medical Systems, Inc. has announced preliminary, unaudited results for the second quarter of 2024, expecting revenues of $195.9 million, a 30% increase from the previous year. The U.S. revenue alone is anticipated to be $187.8 million, signaling robust growth. The company has updated its full-year revenue outlook, now estimating between $788 million and $798 million for 2024, which is an increase from earlier projections. A complete financial report will be released on August 6, 2024.
Read more →INSP▲ +9.2%on this news
Inspire Medical Systems, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2023 and Provides Initial 2024 Guidance
Inspire Medical Systems, Inc. reported preliminary unaudited revenue results for Q4 2023 and full year 2023, showing significant growth. The company anticipates a revenue increase of approximately 40% in Q4 compared to the previous year and a total revenue for 2023 of around $625 million. Inspire has activated 78 new centers and created 13 new sales territories in the U.S. Looking ahead, the company projects a revenue growth of 24% to 26% for 2024. These positive results reflect the successful execution of their business strategy and operational leverage.
Read more →INSPInspire Medical Systems, Inc. Announces Appointment of Seasoned Medical Device Executive Myriam J. Curet, M.D. to its Board of Directors Company adds further expertise in medical device industry R&D, regulatory affairs a
Inspire Medical Systems, Inc. announced the appointment of Dr. Myriam J. Curet as an independent Director effective December 21, 2023. Dr. Curet, a practicing board-certified surgeon and executive at Intuitive Surgical, brings significant leadership experience in developing minimally invasive surgical solutions. Her background includes faculty positions at Stanford University and the University of New Mexico. This appointment is expected to enhance Inspire's capabilities in advancing treatments for obstructive sleep apnea.
Read more →INSPInspire Medical Systems, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2022
Inspire Medical Systems, Inc. has announced preliminary results for fiscal year 2022, projecting a revenue increase of approximately 75% compared to 2021. For the fourth quarter alone, revenue is expected to be between $137.5 million to $137.9 million, significantly boosting the company's growth trajectory. The company activated 61 new medical centers and created 16 new sales territories during this period, underscoring its commitment to expand its market presence. Inspire's upcoming earnings announcement is anticipated for February 7, 2023.
Read more →INSPInspire Medical Systems, Inc. to Report Third Quarter 2022 Financial Results on November 1, 2022
Inspire Medical Systems, Inc. will announce its third quarter 2022 financial results on November 1, 2022. A conference call will follow at 5:00 p.m. ET to discuss these results and recent business developments. The call will be accessible via a link provided by the company, and a replay will be available afterward.
Read more →INSPInspire Medical Systems, Inc. Announces Updates from International Surgical Sleep Society and American Academy of Otolaryngology – Head and Neck Surgery Meetings
Inspire Medical Systems, Inc. announced significant updates from the ISSS and AAO-HNSF meetings held in Philadelphia. The company highlighted innovative enhancements to its Inspire platform, including new technology for less invasive procedures and remote patient management. Over 30 presentations showcased the efficacy of Inspire's treatment for obstructive sleep apnea, reinforcing its commitment to improving patient outcomes.
Read more →INSPInspire Medical Systems, Inc. to Present at the Wells Fargo 2022 Healthcare Conference
Inspire Medical Systems, Inc. will present at the Wells Fargo 2022 Healthcare Conference on September 8, 2022. The presentation will highlight their innovative solutions for obstructive sleep apnea, including their FDA-approved Inspire therapy. Attendees can access the presentation via a live webcast, with a replay available afterward.
Read more →INSPInspire Medical Systems, Inc. Announces Appointment of Ezgi Yagci as Vice President of Investor Relations
Inspire Medical Systems has appointed Ezgi Yagci as Vice President of Investor Relations, effective August 15, 2022. Yagci, who has over 15 years of experience in the medical technology sector, previously worked at Zimmer Biomet. Her role will focus on enhancing investor relations and supporting the company's growth strategy, particularly in addressing obstructive sleep apnea.
Read more →INSPInspire Medical Systems, Inc. Announces Pricing of Offering of Common Stock
Inspire Medical Systems, Inc. has announced the pricing of a public offering of 1,000,000 shares of common stock at $215.00 per share. The offering includes a 30-day option for underwriters to purchase an additional 150,000 shares. The offering is set to close on August 16, 2022, subject to customary conditions.
Read more →INSPInspire Medical Systems, Inc. Announces Second Quarter 2022 Financial Results and Updates 2022 Outlook
Inspire Medical Systems reported a strong second quarter for 2022, with revenues reaching $91.4 million, a 73% increase from the previous year. The company announced regulatory approvals for expanded MRI compatibility and new silicone leads, which are expected to enhance product performance. Inspire also raised its full year revenue guidance to between $354 million and $362 million, reflecting positive market trends despite ongoing challenges.
Read more →INSPInspire Medical Systems, Inc. Announces Appointment of Two New Independent Directors to its Board
Inspire Medical Systems has appointed Cynthia Burks and Charisse Sparks, M.D., as independent directors to its Board, effective July 28, 2022. Burks, former Chief Human Resources Officer at Genentech, brings extensive HR experience, while Dr. Sparks, Chief Medical Officer at AppliedVR, adds valuable medical device industry expertise. These appointments expand the board to 11 directors, enhancing its strategic capabilities.
Read more →INSPInspire Medical Systems, Inc. Announces FDA Approval of Expanded, Full-Body MRI Compatibility with Inspire Therapy
Inspire Medical Systems has received FDA approval for expanded MRI compatibility with its Inspire therapy, allowing full-body scans. This retroactive approval applies to all patients with the Inspire IV neurostimulator device, enhancing treatment options for obstructive sleep apnea. The CEO emphasized that this development addresses previous concerns regarding MRI access for patients.
Read more →INSPInspire Medical Systems, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2021
Inspire Medical Systems, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2021 MINNEAPOLIS, Minnesota - January 4, 2022 - Inspire Medical Systems, Inc. (NYSE INSP) ( Inspire ), a medical technology company focused on the development and commercialization
Read more →INSPInspire Medical Systems, Inc. Announces Positive Coverage Policy Issued by Anthem for Inspire Therapy
Inspire Medical Systems, Inc. Announces Positive Coverage Policy Issued by Anthem for Inspire Therapy MINNEAPOLIS, Minnesota - May 20, 2021 - Inspire Medical Systems, Inc. (NYSE INSP) ( Inspire ), a medical technology company focused on the development and commercialization of
Read more →INSPInspire Medical Systems, Inc. Provides First Quarter and Full Year 2020 Update
Inspire Medical Systems, Inc. Provides First Quarter and Full Year 2020 Update MINNEAPOLIS, Minnesota - April 13, 2020 - Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative and min
Read more →INSPInspire Medical Systems, Inc. Announces First Quarter 2019 Financial Results and Increases 2019 Outlook
Inspire Medical Systems, Inc. Announces First Quarter 2019 Financial Results and Increases 2019 Outlook MINNEAPOLIS, Minnesota - May 7, 2019 - Inspire Medical Systems, Inc. (NYSE INSP) ( Inspire ), a medical technology company focused on the development and commercialization of
Read more →INSPInspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2018 Financial Results
Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2018 Financial Results MINNEAPOLIS, Minnesota - February 26, 2019 - Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innov
Read more →INSPInspire Medical Systems, Inc. Announces Third Quarter 2018 Financial Results and Updates 2018 Outlook
Inspire Medical Systems, Inc. Announces Third Quarter 2018 Financial Results and Updates 2018 Outlook MINNEAPOLIS, Minnesota - November 6, 2018 - Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization
Read more →INSPInspire Medical Systems, Inc. to Have Significant Presence at American Academy of Otolaryngology - Head Neck Surgery Annual Meeting & OTO Experience 2018 MINNEAPOLIS
Inspire Medical Systems, Inc. to Have Significant Presence at American Academy of Otolaryngology - Head Neck Surgery Annual Meeting & OTO Experience 2018 MINNEAPOLIS, October 2, 2018 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology
Read more →INSPInspire Medical Systems, Inc. s Company Presentation September 2018 NYSE: INSP Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Inspire Medical Systems, Inc. s Company Presentation September 2018 NYSE: INSP Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts ar
Read more →INSPInspire Medical Systems, Inc. Announces Second Quarter 2018 Financial Results
Inspire Medical Systems, Inc. Announces Second Quarter 2018 Financial Results MINNEAPOLIS, Minnesota August 7, 2018 Inspire Medical Systems, Inc. (NYSE: INSP) ( Inspire ), a medical technology company focused on the development and commercialization of innovative and minimally i
Read more →Competitive Position
How INSP ranks across every disease it competes inCompetitive Position is a premium feature
See how INSP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial